PSIVIDA CORP

Type: Company
Name: PSIVIDA CORP (pSivida Limited)
First reported Apr 15 2014 - Updated Apr 15 2014 - 3 reports

Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog

The Prescription Drug User Fee Act (PDUFA) date for Alimera and pSivida Corp. 's ( PSDV ) Iluvien is now set for Sep 26, 2014.We note that Alimera had suffered a setback in Oct 2013 when it received the third CRL from the FDA. The FDA refused to approve ... [Published Nasdaq - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

pSivida partner gets new PDUFA date for Iluvien

pSivida (ASX:PVA) licensee Alimera Sciences will know by late September whether the US FDA has approved the company’s fourth new drug application for diabetic macular edema (DME) treatment Iluvien.The regulator has set a new Prescription Drug User Fee ... [Published Australian Life Scientist - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences

By a News Reporter-Staff News Editor at Clinical Trials Week -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, announced that pSivida's president and chief executive officer, ... [Published HispanicBusiness.com - Apr 10 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

pSivida President and CEO Paul Ashton to Present at World Ophthalmology Conference and SMi Conference on Biosimilars and Biobetters

pSivida announced that pSivida's president and chief executive officer Paul Ashton will discuss pSivida's Tethadur technology designed at The World Ophthalmology Conference in Tokyo, through April 6 and at the SMi Inaugural Conference on Biosimilars and ... [Published Individual.com - Apr 04 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 6 reports

pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences

pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences ... [Published Noodls - Apr 01 2014]
Entities: PSIVIDA CORP, Biologics
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

pSivida partner files fourth US NDA for Iluvien

Alimera Sciences has once more resubmitted a New Drug Application (NDA) in the US for Iluvien, a treatment for diabetic macular edema that uses a pSivida (ASX:PVA) insert.The new resubmission addresses the concerns addressed in the US FDA’s latest knockback ... [Published Australian Life Scientist - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

SMi Group Biosimilars & Biobetters USA Event Set to Help Delegates Capitalise on $54 Billion Market

Biosimilars and Biobetters USAPRA International & pSivida Corp to sponsor event taking place 7th & 8th April in Iselin, New JerseyISELIN , NEW JERSEY , USA, March 28, 2014 / EINPresswire.com / -- 28th March 2014: The global biosimilars & Biobetters market ... [Published Mesothelioma News Today - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 1 reports

Alimera makes fourth bid for eye treatment approval from FDA

March 27 (Reuters) - Alimera Sciences Inc said it has applied a fourth time for U.S. regulatory approval to start selling an eye implant that delivers a drug to treat a form of blindess in diabetes patients.Alimera said it had provided a safety update ... [Published CNBC - Mar 27 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 6 reports

Mass. Mover PSivida tries again to win FDA approval

Continue reading belowWatertown-based pSivida Corp. has resubmitted its application for approval to market Iluvien, a treatment for diabetic macular edema, a potentially blinding condition that affects about one million Americans. In October, the Food ... [Published Boston Globe - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

RA Capital Management Discloses New Stake in SANUWAVE Health Inc. (SNWV); Boosts Position in pSivida Corp. (PSDV)

In two recent filings with the U.S. Securities and Exchange Commission, Peter Kolchinsky ’s RA Capital Management has revealed a new position in SANUWAVE Health Inc. (OTCBB: SNWV ) and  raising its stake in  pSivida Corp. (NASDAQ: PSDV ).  In the first ... [Published InsiderMonkey.com - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

SC 13G - pSivida Corp. (0001314102) (Subject)

Document Format FilesSeq Description Document Type Size 1 SC 13G v372557_13g.htm SC 13G 52503 2 JOINT FILING AGREEMENT v372557_ex99-1.htm EX-1 5439 Complete submission text file 0001144204-14-017375.txt 59541 ... [Published SEC - Mar 24 2014]
Entities: PSIVIDA CORP
First reported Mar 21 2014 - Updated Mar 21 2014 - 2 reports

Alimera Vs. pSivida, A Comprehensive Comparison

By Alberto Savrieno :Much has been written about pSivida ( PSDV ) since the FDA surprisingly entered into labeling discussions with the company about ILUVIEN, the ocular insert for diabetic macular edema. The labeling discussions came after a third failure ... [Published BioPortfolio - Mar 21 2014]

Quotes

...Ashton. "We believe our Tethadur technology may provide a solution for sustained-release delivery of many of these molecules. We are pleased with our preclinical in vitro results to date and expect to report data from animal studies by the end of this summer."
Ophthalmologists and rheumatologists have a good deal of patient crossover. "Most of the inflammatory diseases we treat as rheumatologists can have ophthalmologic manifestations" said Christopher M Wise, MD, professor of internal medicine, rheumatology, allergy and immunology, Virginia Commonwealth University School of Medicine...
pSivida president and chief executive officer Paul Ashton said the acceptance of ILUVIEN for DME by the NHS Scotland is great news. "This follows the November 2013 recommendation of ILUVIEN by the U KU K National Institute for Health and Care Excellence (NICE) as an option for this indication and rapid implementation of the recommendation by the NHS in England" Ashton said...
Yahoo – Co. reports malware-infected ads issue larger than previously reported. Co. said "Upon further investigation of the recent ad malware incident, we now know that users may have been impacted between December 27, 2013 - January 3, 2014. While the bulk of those exposed to the malicious advertisements were on European sites, a small fraction of users outside of this region may have been impacted as well.  "

More Content

All (97) | News (42) | Reports (0) | Blogs (53) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Alimera/pSivida Seek FDA Approval for Iluvien -... [Published Nasdaq - Apr 15 2014]
Alimera/pSivida Seek FDA Approval for Iluvien -... [Published Zacks.com - Apr 15 2014]
Alimera/pSivida Seek FDA Approval for Iluvien [Published Zacks.com - Apr 15 2014]
pSivida partner gets new PDUFA date for Iluvien [Published Australian Life Scientist - Apr 15 2014]
pSivida CEO says FDA approval of Iluvien will h... [Published Business First of Buffalo - Apr 14 2014]
pSivida Announces September 26, 2014 PDUFA Date... [Published Benzinga.com - Apr 14 2014]
pSivida Announces September 26, 2014 PDUFA Date... [Published Business Wire - Apr 14 2014]
pSivida Announces September 26, 2014 PDUFA Date... [Published Business Wire Health News - Apr 14 2014]
RA Capital Reports New 5.8% Position In Recentl... [Published InsiderMonkey.com - Apr 10 2014]
pSivida CEO to Discuss Company's Sustained Rele... [Published HispanicBusiness.com - Apr 10 2014]
pSivida President and CEO Paul Ashton to Presen... [Published Individual.com - Apr 04 2014]
Ra Capital Management Reveals New Stake in Enan... [Published InsiderMonkey.com - Apr 02 2014]
pSivida CEO to Discuss Company's Sustained Rele... [Published Noodls - Apr 01 2014]
PSIVIDA : CEO to Discuss Company’s Sustained Re... [Published 4 Traders - Apr 01 2014]
pSivida CEO to Discuss Company’s Sustained Rele... [Published EON Science - Apr 01 2014]
pSivida CEO to Discuss Company’s Sustained Rele... [Published BioPortfolio - Apr 01 2014]
pSivida CEO to Discuss Company’s Sustained Rele... [Published Business Wire Science: Science News - Apr 01 2014]
pSivida CEO to Discuss Company’s Sustained Rele... [Published Business Wire Health News - Apr 01 2014]
pSivida partner files fourth US NDA for Iluvien [Published Australian Life Scientist - Mar 31 2014]
SMi Group Biosimilars & Biobetters USA Event Se... [Published Mesothelioma News Today - Mar 28 2014]
Mass. Mover PSivida tries again to win FDA appr... [Published Boston Globe - Mar 28 2014]
EXAS Gets FDA Panel's Thumbs Up, NRX Ropes In P... [Published RTTNews.com - Mar 28 2014]
Eye Treatment Iluvien (Fluocinolone Intravitrea... [Published P&T Community - Mar 28 2014]
Alimera resubmits NDA for Iluvien [Published Pharma Letter - Mar 27 2014]
pSivida Announces Resubmission of New Drug Appl... [Published Noodls - Mar 27 2014]
PSivida announces resubmission of an applicatio... [Published boston.com - Mar 27 2014]
Alimera makes fourth bid for eye treatment appr... [Published CNBC - Mar 27 2014]
pSivida : Announces Resubmission of New Drug Ap... [Published 4 Traders - Mar 27 2014]
pSivida Announces Resubmission of New Drug Appl... [Published Business Wire Health News - Mar 27 2014]
Martin Whitman, Third Avenue Management Boost S... [Published InsiderMonkey.com - Mar 25 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
pSivida Announces September 26, 2014 PDUFA Date... [Published Business Wire Health News - Apr 14 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida announces September 26, 2014 PDUFA date for Iluvien for DME ...
pSivida CEO to Discuss Company’s Sustained Rele... [Published EON Science - Apr 01 2014]
WATERTOWN, Mass.--(EON: Enhanced Online News)--pSivida CEO to discuss Tethadur biologics delivery system technology at two upcoming conferences ...
pSivida CEO to Discuss Company’s Sustained Rele... [Published Business Wire Science: Science News - Apr 01 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida CEO to discuss Tethadur biologics delivery system technology at two upcoming conferences ...
pSivida CEO to Discuss Company’s Sustained Rele... [Published Business Wire Health News - Apr 01 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida CEO to discuss Tethadur biologics delivery system technology at two upcoming conferences ...
pSivida Announces Resubmission of New Drug Appl... [Published Business Wire Health News - Mar 27 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida announces resubmission of NDA for ILUVIEN for DME ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Drug Availability, Clinical Trial Partnerships,... [Published Financial Services - Dec 24 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.